Patients treated with metformin for diabetes are at a higher risk for developing a vitamin B12 deficiency, according to new research published in the journal BMJ. Metformin is the most commonly prescribed first-line therapy for patients with type 2 diabetes, and is sold under such brand names as Glucophage, Fortamet, Glumetza, and Riomet.
Patients treated with metformin for diabetes are at a higher risk for developing a vitamin B12 deficiency, according to new research published in the journal BMJ. Metformin is the most commonly prescribed first-line therapy for patients with type 2 diabetes, and is sold under such brand names as Glucophage, Fortamet, Glumetza, and Riomet.